Literature DB >> 11979395

Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.

L De Marinis1, A Mancini, A Bianchi, R Gentilella, D Valle, A Giampietro, P Zuppi, C Anile, G Maira, A Giustina.   

Abstract

The objective of this study was to investigate the relationship between growth hormone (GH) dynamic tests (thyrotropin-releasing hormone [TRH] test and oral glucose tolerance test [OGTT]), insulin-like growth factor-I (IGF-I) plasma values, tumor size, and clinical outcome in patients with GH-secreting pituitary adenomas. Furthermore, we investigated the potential prognostic utility of the above biochemical parameters in the follow-up of patients with acromegaly. We studied 50 acromegalic patients (18 males and 32 females; mean age, 40 years; range, 16 to 69) who underwent trans-sphenoidal removal of a GH-secreting pituitary adenoma from 1990 to 1994. Preoperatively, we evaluated (1) GH plasmatic levels after an oral glucose load (OGTT) (blood samples were drawn at -15, 0, 30, 60, 90, 120, 150, and 180 minutes after oral administration of 0.75 g/kg body weight [BW] of glucose), (2) GH plasma levels after a TRH test (200 microg as an intravenous [IV] bolus), and (3) basal IGF-I plasma levels after an overnight fast. From 3 to 12 months after surgery we evaluated (1) GH plasma values after an OGTT, and (2) basal plasma IGF-I, free triiodothyronine (FT(3)), free thyroxine (FT(4)), thyroid-stimulating hormone (TSH), and urinary free cortisol. The same tests were performed every year for 5 years. All of the patients were classified into 4 subgroups according to the system of Hardy and Vezina. Preoperatively, "controlled" patients (n = 29) had a GH paradoxical response to TRH (n = 28) and an unresponsiveness to OGTT (n = 29); 23 of them belonged to the I and II classes. Only 5 poorly controlled patients (n = 21) showed a preoperative paradoxical response to TRH and 9 had a preoperative GH partial inhibition after OGTT; 19 of them belonged to the III and IV classes. Our data suggest that in the preoperative period in acromegalic patients the simultaneous presence of a GH paradoxical response to TRH and lack of GH inhibition after OGTT is inversely related to the tumor size and therefore more likely to be restored to normal by surgical treatment. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11979395     DOI: 10.1053/meta.2002.32017

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  10 in total

1.  Basal and glucose-suppressed GH levels less than 1 microg/L in newly diagnosed acromegaly.

Authors:  Pamela U Freda; Carlos M Reyes; Abu T Nuruzzaman; Robert E Sundeen; Jeffrey N Bruce
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 2.  Clinical implications of growth hormone-secreting tumor subtypes.

Authors:  Katja Kiseljak-Vassiliades; Shibana Shafi; Janice M Kerr; Tzu L Phang; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Endocrine       Date:  2012-03-21       Impact factor: 3.633

Review 3.  The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes.

Authors:  Daniela Regazzo; Mattia Barbot; Carla Scaroni; Nora Albiger; Gianluca Occhi
Journal:  Rev Endocr Metab Disord       Date:  2020-03       Impact factor: 6.514

4.  Characterization of sporadic somatotropinomas with high GIP receptor expression.

Authors:  Olivia Faria; Renan Lyra Miranda; Carlos Henrique de Azeredo Lima; Alexandro Guterres; Nina Ventura; Monique Alvares Barbosa; Aline Helen da Silva Camacho; Elisa Baranski Lamback; Felipe Andreiuolo; Leila Chimelli; Leandro Kasuki; Mônica R Gadelha
Journal:  Pituitary       Date:  2022-09-06       Impact factor: 3.599

Review 5.  Pitfalls in the biochemical assessment of acromegaly.

Authors:  Pamela U Freda
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 6.  Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?

Authors:  Pamela U Freda
Journal:  Clin Endocrinol (Oxf)       Date:  2009-02-18       Impact factor: 3.478

Review 7.  Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly.

Authors:  Laure Cazabat; Jean-Claude Souberbielle; Philippe Chanson
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 8.  Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences.

Authors:  Martin Bidlingmaier; Pamela U Freda
Journal:  Growth Horm IGF Res       Date:  2009-10-08       Impact factor: 2.372

Review 9.  Growth hormone measurements in the diagnosis and monitoring of acromegaly.

Authors:  Akira Sata; Ken K Y Ho
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

10.  Investigation of responsiveness to thyrotropin-releasing hormone in growth hormone-producing pituitary adenomas.

Authors:  Sang Ouk Chin; Sang Youl Rhee; Suk Chon; You-Cheol Hwang; In-Kyung Jeong; Seungjoon Oh; Sung-Woon Kim
Journal:  Int J Endocrinol       Date:  2013-11-21       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.